EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthesis, Anticancer Activity, and In Silico Studies of 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine Analogs

Mohamed Jawed Ahsan iD, Krishna Gautam, Amena Ali iD, Abuzer Ali iD, Abdulmalik Saleh Alfawaz Altamimi, Salahuddin iD, Manal A Alossaimi iD, S V V N S M Lakshmi, Md Faiyaz Ahsan

Molecules · 2023

DOI: 10.3390/molecules28196936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Mohamed Jawed Ahsan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Ambabari Circle, Jaipur 302039, Rajasthan, India. Hauptthemen laut MEDLINE: Tubulin, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taif University, Deanship of Scientific Research, Taif University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the current study, we described the synthesis of ten new 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine analogs (4a–j), as well as their characterization, anticancer activity, molecular docking studies, ADME, and toxicity prediction. The title compounds (4a–j) were prepared in three steps, starting from substituted anilines in a satisfactory yield, followed by their characterization via spectroscopic techniques. The National Cancer Institute (NCI US) protocol was followed to test the compounds’ (4a–j) anticancer activity against nine panels of 58 cancer cell lines at a concentration of 10−5 M, and growth percent (GP) as well as percent growth inhibition (PGI) were calculated. Some of the compounds demonstrated significant anticancer activity against a few cancer cell lines. The CNS cancer cell line SNB-75, which showed a PGI of 41.25 percent, was discovered to be the most sensitive cancer cell line to the tested compound 4e. The mean GP of compound 4i was found to be the most promising among the series of compounds. The five cancer cell lines that were found to be the most susceptible to compound 4i were SNB-75, UO-31, CCRF-CEM, EKVX, and OVCAR-5; these five cell lines showed PGIs of 38.94, 30.14, 26.92, 26.61, and 23.12 percent, respectively, at 10−5 M. The inhibition of tubulin is one of the primary molecular targets of many anticancer agents; hence, the compounds (4a–j) were further subjected to molecular docking studies looking at the tubulin–combretastatin A-4 binding site (PDB ID: 5LYJ) of tubulin. The binding affinities were found to be efficient, ranging from −6.502 to −8.341 kcal/mol, with two major electrostatic interactions observed: H-bond and halogen bond. Ligand 4i had a binding affinity of −8.149 kcal/mol with the tubulin–combretastatin A-4 binding site and displayed a H-bond interaction with the residue Asn258. The ADME and toxicity prediction studies for each compound were carried out using SwissADME and ProTox-II software. None of the compounds’ ADME predictions showed that they violated Lipinski’s rule of five. All of the compounds were also predicted to have LD50 values between 440 and 500 mg/kg, putting them all in class IV toxicity, according to the toxicity prediction. The current discovery could potentially open up the opportunity for further developments in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TubulinAntineoplastic AgentsStructure-Activity RelationshipMolecular Docking SimulationCell Line, TumorAminesDrug Screening Assays, AntitumorCell ProliferationMolecular StructureStilbenes

Stichwörter der Autor:innen

ADME studiesanticancercell linesmolecular dockingtriazoletubulin

Substanzen

TubulinAminesAntineoplastic AgentsfosbretabulinStilbenes

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Ambabari Circle, Jaipur 302039, Rajasthan, India.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia.
  • Department of Pharmacognosy, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-2, Greater Noida 201306, Uttar Pradesh, India.
  • Department of Pharmacognosy, Vishnu Institute of Pharmaceutical Education & Research, Narsapur 502313, Medak Dist., Telangana, India.

ORCID-Profile: Mohamed Jawed Ahsan, Amena Ali, Abuzer Ali, Salahuddin, Manal A Alossaimi

Förderung

  • Taif University
  • Deanship of Scientific Research, Taif University

Zitieren

APA

Ahsan, M. J., Gautam, K., Ali, A., Ali, A., Altamimi, A. S. A., Salahuddin, Alossaimi, M. A., Lakshmi, S. V. V. N. S. M., & Ahsan, M. F. (2023). Synthesis, Anticancer Activity, and In Silico Studies of 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine Analogs. Molecules. https://doi.org/10.3390/molecules28196936

Vancouver

Ahsan MJ, Gautam K, Ali A, Ali A, Altamimi ASA, Salahuddin, et al. Synthesis, Anticancer Activity, and In Silico Studies of 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine Analogs. Molecules. 2023. doi:10.3390/molecules28196936

BibTeX
@article{Ahsan2023,
  author = {Ahsan, Mohamed Jawed and Gautam, Krishna and Ali, Amena and Ali, Abuzer and Altamimi, Abdulmalik Saleh Alfawaz and Salahuddin and Alossaimi, Manal A and Lakshmi, S V V N S M and Ahsan, Md Faiyaz},
  title = {Synthesis, Anticancer Activity, and In Silico Studies of 5-(3-Bromophenyl)-N-aryl-4H-1,2,4-triazol-3-amine Analogs},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28196936}
}
Kostenlos starten →